US Representative

Blaine Luetkemeyer 2023-2024 Regular Session - Authored & Sponsored Legislation (Page 6)

Legislative Session

Co-Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4035

Introduced
6/12/23  
Protecting Small Business Information Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4036

Introduced
6/12/23  
Accountability through Confirmation Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4132

Introduced
6/14/23  
Refer
6/14/23  
Report Pass
6/21/23  
Falun Gong Protection Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4157

Introduced
6/15/23  
Refer
6/15/23  
Not Just a Number Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4189

Introduced
6/15/23  
Refer
6/15/23  
CONNECT for Health Act of 2023 Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4198

Introduced
6/16/23  
Protecting Consumers from Abusive Mortgage Leads Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB427

Introduced
1/20/23  
Refer
1/20/23  
Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB431

Introduced
1/20/23  
Life at Conception Act This bill declares that the right to life guaranteed by the Constitution is vested in each human being at all stages of life, including the moment of fertilization, cloning, or other moment at which an individual comes into being. Nothing in this bill shall be construed to authorize the prosecution of any woman for the death of her unborn child.
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4335

Introduced
6/23/23  
VA Loan Informed Disclosure Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4346

Introduced
6/23/23  
Small Bank Holding Company Relief Act of 2023
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4362

Introduced
6/23/23  
Refer
6/23/23  
Refer
6/23/23  
Saving Organs One Flight at a Time Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4417

Introduced
6/30/23  
Ending Agricultural Trade Suppression Act

Primary Sponsor of Legislation

US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4252

Introduced
6/21/23  
Protecting Education Privacy Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4341

Introduced
6/23/23  
Ukraine Reconstruction Accountability and Transparency Act
US

Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4428

Introduced
6/30/23  
Refer
6/30/23  
Guidance Clarity Act